Abstract:
Modified oligonucleotides comprising CpG sites, wherein the cytosine is replaced by cytosine analogs are provided as well as methods of making the oligonucleotides and their use in inhibiting DNA Methyltransferase, inhibiting or reversing methylation of genes and in treating cancer, tumorigenesis and hyper-proliferative disorders.
Abstract:
The invention relates to medicine and veterinary science. The inventive method for treating diseases associated with modifications of the qualitative and/or quantitative composition of blood extracellular DNA, namely oncological diseases, infection diseases provoked by bacteria, fungi and protozoa, atherosclerosis, pancreatic diabetes, allergic diseases associated with delayed response hypersensitivity and diseases due to somatic cell gene mutations consists in injecting a blood extracellular DNA binding agent in a systemic blood circulation. In a second variant, an agent modifying the chemical composition and/or conformation and/or polymery of the blood extracellular DNA without destruction thereof is injected into a systemic blood circulation. In a third variant, an agent stimulating the synthesis and/or the activity of endogenic biopolymers which bind or destroy or modify the chemical composition and/or conformation and/or polymery of the blood extracellular DNA without destruction thereof is injected into a systemic blood circulation.
Abstract:
A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).
Abstract:
The present disclosure relates to methods of treating AML associated with DNMT3A mutations by administering one or more DOTIL inhibitors or related pharmaceutical compositions to subjects in need thereof.
Abstract:
The present disclosure relates to a method for increasing biomass synthesis capacity of microorganisms. The method in accordance with the present disclosure comprises overexpressing the genes involved in protein synthesis to increase the levels of protein synthesis and thereby, increase the biomass synthesis capacity of the microorganisms. The present disclosure also provides a modified microorganism having increased biomass synthesis capacity.